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Dr Harold M. Burkhart (Oklahoma City, Okla). Dr Dabal and
colleagues from the University of Alabama continue their quest for
the perfect Fontan in their most recent series update. They present
a 25-year Fontan experience involving more than 200 patients with
excellent survival and an extremely low risk of reoperation. Of
note, they demonstrate no increasing phase of risk after 20 years.
Congratulations on the excellent results and the very nice
presentation.
I have 3 questions.
First, we all know that picking the perfect patient is the first step
to a perfect Fontan result. Could you please discuss your current
exclusion criteria for offering a Fontan operation; specifically,
where do atrioventricular valve regurgitation, ventricular dysfunc-
tion, and marginal pulmonary architecture fit in? What percentage
of your patients initially planned for the Fontan pathways are
ultimately denied the operation?
Dr Dabal. Thank you for your comments and thank you for
your questions. The first question is an excellent one. If you
look at our series and you look at the last publication from our
institution on our Fontan results, the percentage of patients that
do not ultimately end up with a Fontan palliation who initially
begin on that pathway is in the neighborhood of 15%. And I think
that you have mentioned the main reasons why patients do not
make it: decreased cardiac function; unfavorable pulmonary
vasculature or high pulmonary artery pressures; significant
atrioventricular valve regurgitation. Those are probably the 3
biggest factors that would preclude us from performing a Fontan.
Dr Burkhart.My second question is along the same lines as the
first question. I note, as you noted, 10% of your patients, or less
than, had hypoplastic left heart syndrome and they have a lot of
the problems that we discussed earlier in the exclusion
criteria. Given that most large series typically have a higher
proportion, could you first explain why yours does not have that
proportion; and furthermore, do you think that if you did have
that proportion your results would be different?
Dr Dabal. So the hypoplastic population is definitely only
represented in the latter part of our experience. Until about
2005, those patients were not having Norwoods in Alabama, so
that is why they are somewhat underrepresented in the population.
Based on our multivariable analysis, however, morphology did
not make any difference in survival. It was not a risk factor for
mortality. I think that certainly as we get increasing length of
follow-up this may change, but I think that there are plenty of
data out there to suggest from multiple institutions that ventricular
morphology is not necessarily a risk factor for poor late-term
outcomes.diovascular Surgery c Volume 148, Number 6 2523
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DDr Burkhart. And my final question is a technical one. I note
that the average age of Fontan in your group is almost 5 years;
however, the most common conduit size is 16 mm. As you
know, some have argued for larger conduits especially in larger pa-
tients. Would you please discuss your current approach to and
reasoning behind your conduit choice.
Dr Dabal. Well, I think that the conduit choice has been a
personal preference, but it is borne out by the literature. If you
look at a lot of the computational analyses of flow characteristics
of 16-mm tubes, it has been shown that those are preferable to
larger tubes in terms of lower risk of stasis and risk of thrombosis
related to that stasis. I think that our experience has been somewhat
skewed by the era effect. If you look at the latter era, our median
age of operation is probably significantly lower than 4.6 years,
probably closer to the 2- to 3-year age range. And the bottom
line is a 16-mm conduit is almost always easily put into a child
at that size. Our long-term results have shown that it really does
not make much difference, that the results are as good or better
with a 16-mm tube as they are with an 18- or 20-mm tube, and
so that is our logic for doing that.
Dr Sertac M. Cicek (Istanbul, Turkey). Congratulations on the
excellent results. You stated that almost 50% of the patients
had a fenestration, 45% exactly. What are your indications for
fenestration? This is a significantly high incidence of fenestration
for such a group of patients.
Dr Dabal. Thank you for the question. I think that that is
another factor that has changed significantly over the experience
at the University of Alabama at Birmingham. Earlier in the
experience there was routine fenestration for most patients;
however, over the last 5 to 10 years we have been much more
selective with our application of fenestrations. Currently, our
indications are similar to what we would consider to be high-risk
Fontans. So any patient who has decreased function, a significant
amount of atrioventricular valve regurgitation, or unfavorable
pulmonary artery anatomy, those are the 3 categories of patients
that we would consider fenestrating.
Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). When
you performed your era analysis, what was the decision
making for the year that you chose to separate the 2 groups
into the 2 eras?
Dr Dabal. I think we basically split it down the middle.
Dr Hirsch-Romano. Was there a change in surgical technique
or management strategy at that time?
Dr Dabal. No, there really was not. The only significant
change during the period was the transition from intracardiac to2524 The Journal of Thoracic and Cardiovascular Surextracardiac tubes, but there was no change really in the middle
or latter part of the study period.
Dr Hillel Laks (Los Angeles, Calif). I enjoyed your talk very
much. I would just caution about the 16-mm graft. In our
experience we have had 1 reoperation for a 16-mm graft and this
was in a female who was quite tall. It occurred when she was
adult size, about 1.7 m tall. But this was a patient who had a
fenestration that was subsequently closed with an Amplatzer
device, and potentially the addition of some added encroachment
on the lumen made a difference; she had about a 5-mm gradient
across it. So I would say that we now prefer always using an
18-mm or a 20-mm graft wherever possible. But in younger
children, sometimes it is difficult to get a 16-mm graft into a
3-year-old who is small; in that case it may be worthwhile waiting
longer until the child is bigger, and particularly if it is a boy with
large parents and you are expecting that child to become quite
large. I think that a 16-mm graft in a full-size adult with a big
body surface area is going to be inadequate and it is worthwhile
trying to put a larger graft in.
Dr Dabal. Thank you for your comment.
Dr Carl L. Backer (Chicago, Ill). Apropos the presentations
here on Saturday morning where we discussed extracardiac Fontan
versus lateral tunnel; it seems that your paper is a very nice
addition to the literature supporting extracardiac Fontan. I want
to take the opportunity to survey this very august group. How
many surgeons primarily use the extracardiac Fontan approach
when they do a Fontan operation?
(Show of hands.)
All right. How many surgeons use the lateral tunnel?
(Show of hands.)
It looks like you have now convinced a few more surgeons.
For the primary Fontan, it looked to me that about 80% of
surgeons are doing extracardiac and 20% are doing the lateral
tunnel.
The second thing I noticed in your study was that 81% of
your patients are on aspirin, which has been our institutional
strategy. I would like to survey this group; how many are
keeping their patients solely on aspirin after the Fontan operation?
(Show of hands.)
It looks like a pretty sizable number of hands.
And how many are on warfarin?
(Show of hands.)
My read on this is that about 70% of people are putting their
patient on aspirin after a Fontan operation and maybe 25% to
30% on warfarin.gery c December 2014
